Current Rheumatology Reports

, Volume 13, Issue 4, pp 369–375 | Cite as

The Perspective on Psoriatic Arthritis in Asia

Article

Abstract

There is a wide variation in the prevalence, incidence, and clinical manifestation of psoriatic arthritis (PsA) across countries due to genetic and environmental factors. Data on PsA in Asia are limited and come from small cross-sectional studies. The burden of PsA in Asia is high, including poor physical functioning, poor quality of life, and high socioeconomic cost. In addition, high rates of subclinical atherosclerosis and traditional cardiovascular risk factors among PsA patients in Asia have been demonstrated. Preliminary data suggest treatment with tumor necrosis factor blockers may reverse atherosclerosis in PsA. Several outcome measure instruments, including the Medical Outcomes Survey Short Form 36 and Health Assessment Questionnaire, have been validated for measuring PsA burden among the Chinese. A coordinated effort in Asia from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the Asia Pacific League of Associations for Rheumatology (APLAR) will help estimate disease burden and clinical behavior of PsA on that continent.

Keywords

Psoriatic arthritis Asia Epidemiology Premature atherosclerosis 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Tam LS, Leung YY, Li EK. Psoriatic arthritis in Asia. Rheumatology (Oxford). 2009;48:1473–7. This is a carefully written review and update on PsA in Asia. CrossRefGoogle Scholar
  2. 2.
    Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:ii14–7.PubMedCrossRefGoogle Scholar
  3. 3.
    • Zeng QY, Chen R, Darmawan J, et al. Rheumatic diseases in China. Arthritis Res Ther. 2008;10:R17. This is a systematic review of epidemiologic studies in China from the 1980s to 2006. PsA was investigated as a subset of spondyloarthropathies in five studies. PubMedCrossRefGoogle Scholar
  4. 4.
    Thumboo J, Tham SN, Tay YK, et al. Patterns of psoriatic arthritis in Orientals. J Rheumatol. 1997;24:1949–53.PubMedGoogle Scholar
  5. 5.
    Hukuda S, Minami M, Saito T, et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol. 2001;28:554–9.PubMedGoogle Scholar
  6. 6.
    Jamshidi F, Bouzari N, Seirafi H, Farnaghi F, Firroz A. The prevalence of psoriatic arthritis in psoriatic patients in Tehran, Iran. Arch Iran Med. 2008;11:162–5.PubMedGoogle Scholar
  7. 7.
    Baek HJ, Yoo CD, Shin KC, et al. Spondylitis is the most common pattern of psoriatic arthritis in Korea. Rheumatol Int. 2000;19:89–94.PubMedCrossRefGoogle Scholar
  8. 8.
    Prasad PV, Bikku B, Kaviarasan PK, Senthilnathan A. A clinical study of psoriatic arthropathy. Indian J Dermatol Venereol Leprol. 2007;73:166–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Fan X, Yang S, Sun LD, et al. Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol. 2007;87:335–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Kundakci N, Tursen U, Babiker MO, Gurgey E. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. Int J Dermatol. 2002;41:220–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Kawada A, Tezuka T, Nakamizo Y, et al. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci. 2003;31:59–64.PubMedCrossRefGoogle Scholar
  12. 12.
    Tey HL, Ee HL, Tan AS, et al. Risk factors associated with having psoriatic arthritis in patients with cutaneous psoriasis. J Dermatol. 2010;37:426–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Taylor W, Gladman D, Helliwell P, CASPAR Study Group, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–73.PubMedCrossRefGoogle Scholar
  14. 14.
    • Leung YY, Tam LS, Ho KW, et al. Evaluation of the CASPAR criteria for psoriatic arthritis in the Chinese population. Rheumatology (Oxford). 2010;49:112–5. This was the first validation study of CASPAR criteria in PsA of the Han Chinese in Asia. CrossRefGoogle Scholar
  15. 15.
    •• Tam LS, Tomlison B, Chu TT, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology (Oxford). 2008;47:718–23. This was a description of the association of PsA with traditional CV risk factors in the Chinese population; it suggested that PsA may be associated with obesity, hypertension, and insulin resistance due to a shared inflammatory pathway. CrossRefGoogle Scholar
  16. 16.
    Yamamoto T, Yokozeki H, Nishioka K. Clinical analysis of 21 patients with psoriasis arthropathy. J Dermatol. 2005;32:84–90.PubMedGoogle Scholar
  17. 17.
    Moghaddassi M, Shahram F, Chams-Davatchi C, Najafizadeh SR, Davatchi F. Different aspects of psoriasis: analysis of 150 Iranian patients. Arch Iran Med. 2009;12:279–83.PubMedGoogle Scholar
  18. 18.
    Rajendran CP, Ledge SG, Rani KP, Madhavan R. Psoriatic arthritis. J Assoc Physicians India. 2003;51:1065–8.PubMedGoogle Scholar
  19. 19.
    Elkayam O, Segal R, Caspi D. Human leukocyte antigen distribution in Israeli patients with psoriatic arthritis. Rheumatol Int. 2004;24:93–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Tsai YG, Chang DM, Kuo SY, et al. Relationship between human lymphocyte antigen-B27 and clinical features of psoriatic arthritis. J Microbiol Immunol Infect. 2003;36:101–4.PubMedGoogle Scholar
  21. 21.
    Liao HT, Lin KC, Chang YT, et al. Human leukocyte antigen and clinical and demographic characteristics in psoriatic arthritis and psoriasis in Chinese patients. J Rheumatol. 2008;35:891–5.PubMedGoogle Scholar
  22. 22.
    Deesomchok U, Tumrasvin T. Clinical comparison of patients with ankylosing spondylitis, Reiter’s syndrome and psoriatic arthritis. J Med Assoc Thai. 1993;76:61–70.PubMedGoogle Scholar
  23. 23.
    Al-Awadhi AM, Hasan EA, Sharma PN, Haider MZ, Al-Saeid K. Angiotensin-converting enzyme gene polymorphism in patients with psoriatic arthritis. Rheumatol Int. 2007;27:1119–23.PubMedCrossRefGoogle Scholar
  24. 24.
    Feld J, Weiss G, Rosner I, et al. Electrocardiographic findings in psoriatic arthritis: a case-controlled study. J Rheumatol. 2008;35:2379–82.PubMedCrossRefGoogle Scholar
  25. 25.
    Saricaoglu H, Güllülü S, Bülbül Baskan E, Cordan J, Tunali S. Echocardiographic findings in subjects with psoriatic arthropathy. J Eur Acad Dermatol Venereol. 2003;17:414–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Gonzalez-Juanatey C, Amigo-Diaz E, Miranda-Filloy JA, et al. Lack of echocardiographic and Doppler abnormalities in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Semin Arthritis Rheum. 2006;35:333–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Gladman DD, Mease PJ, Strand V, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol. 2007;34:1167–70.PubMedGoogle Scholar
  28. 28.
    •• Mease P. Assessment tools in psoriatic arthritis. J Rheumatol. 2008;35:1426–30. This is a carefully written review article on the commonly used and validated assessment tools for PsA. PubMedGoogle Scholar
  29. 29.
    McKenna SP, Doward LC, Whalley D, et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis. 2004;63:162–9.PubMedCrossRefGoogle Scholar
  30. 30.
    • Leung YY, Ho KW, Zhu TY, Tam LS, Kun EW, Li EK. Testing scaling assumptions, reliability and validity of Medical Outcomes Study Short-Form 36 Health Survey in psoriatic arthritis. Rheumatology (Oxford). 2010;49:1495–501. This was a detailed evaluation of the psychometric properties of the Chinese version of SF-36 for Chinese patients with PsA. CrossRefGoogle Scholar
  31. 31.
    • Leung YY, Tam LS, Kun EW, Ho KW, Li EK. Comparing 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analysis. J Rheumatol. 2008;35:1613–21. This was one of the few studies to utilize item response theory to evaluate the psychometric properties of various measurements of physical functioning in PsA. PubMedGoogle Scholar
  32. 32.
    Leung YY, Tam LS, Kun EW, Li EK. Impact of illness and variables associated with functional impairment in Chinese patients with psoriatic arthritis. Clin Exp Rheumatol. 2008;26:820–6.PubMedGoogle Scholar
  33. 33.
    •• Zhu TY, Tam LS, Leung YY, et al. Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. J Rheumatol. 2010;37:1214–20. This was the first cost evaluation study in PsA from Asia, which demonstrated a high financial burden associated with the disease. Axial PsA was noted to have double the indirect cost. PubMedCrossRefGoogle Scholar
  34. 34.
    Leung YY, Tam LS, Lee KW, et al. Involvement, satisfaction and unmet health care needs in patients with psoriatic arthritis. Rheumatol Oxf. 2009;48:53–6.CrossRefGoogle Scholar
  35. 35.
    Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol. 2008;26 5 Suppl 51:S62-5.PubMedGoogle Scholar
  36. 36.
    Kimhi O, Caspi D, Bornstein NM, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum. 2007;36:203–9.PubMedCrossRefGoogle Scholar
  37. 37.
    •• Eder L, Zisman D, Barzilai M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol. 2008;35:877–82. This case-control study demonstrated that PsA status and other traditional CV risk factors were associated with high IMT and carotid plaques. PubMedGoogle Scholar
  38. 38.
    •• Tam LS, Shang Q, Li EK, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum. 2008;59;1322–31. This was a study illustrating higher carotid IMT among Chinese PsA patients as compared with controls. Subclinical atherosclerosis was present in 35% of PsA patients despite a low CV risk according to FRS. PubMedCrossRefGoogle Scholar
  39. 39.
    •• Tam LS, Li EK, Shang Q, et al. Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis. 2010 Jul 20. (Epub ahead of print). This is some preliminary evidence showing the reversal of subclinical atherosclerosis via treatment with TNF blockers in PsA patients. Google Scholar
  40. 40.
    •• Di Minno MN, Iervolino S, Peluso R, et al; on behalf of the CaRRDs study group. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-{alpha} blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol. 2011 Jan 6. (Epub ahead of print). This was an Italian study with an adequate sample size of 224 PsA patients (120 on TNF-α blockers and 104 on traditional disease-modifying antirheumatic drugs) compared with 305 controls, showing higher carotid IMT in disease-modifying antirheumatic drug–treated than in TNF-α blocker–treated PsA patients. It suggested treatment of inflammation in PsA may hamper the cascade that causes the increased vascular risk in PsA patients. Google Scholar
  41. 41.
    Duffin KC, Chandran V, Gladman DD, et al. Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol. 2008;35:1449–53.PubMedGoogle Scholar
  42. 42.
    •• O’Rielly DD, Rahman P. Where do we stand with the genetics of psoriatic arthritis? Curr Rheumatol Rep. 2010;12:300–8. This is a useful review of up-to-date studies on the genetics of PsA and future prospects. PubMedCrossRefGoogle Scholar
  43. 43.
    •• Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34:J314-21. This is a carefully written review on the epidemiology and genetics of psoriasis and PsA. PubMedCrossRefGoogle Scholar
  44. 44.
    Hamamoto Y, Tateno H, Ishida T, Muto M. Lack of association between promoter polymorphism of the tumor necrosis factor-alpha gene and psoriatic arthritis in Japanese patients. J Invest Dermatol. 2000;115:1162–4.PubMedCrossRefGoogle Scholar
  45. 45.
    Chang YT, Chou CT, Yu CW, et al. Cytokine gene polymorphisms in Chinese patients with psoriasis. Br J Dermatol. 2007;156:899–905.PubMedCrossRefGoogle Scholar
  46. 46.
    Lan CC, Tsai WC, Wu CS, Yu CL, Yu HS. Psoriatic patients with arthropathy show significant expression of free HLA class I heavy chains on circulating monocytes: a potential role in the pathogenesis of psoriatic arthropathy. Br J Dermatol. 2004;151:24–31.PubMedCrossRefGoogle Scholar
  47. 47.
    •• Zhang XJ, Huang W, Yang S, et al. Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet. 2009;41:205–210. This was the first GWAS conducted on psoriasis patients of Chinese ancestry. PubMedCrossRefGoogle Scholar
  48. 48.
    • Sun LD, Cheng H, Wang ZX, et al. Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet. 2010;42:1005–9. This was the extension GWAS study of a large sample size from China; results were compared with those from Germany and the United States. It highlighted again the heterogeneity of disease susceptibility between Chinese and European populations. PubMedCrossRefGoogle Scholar
  49. 49.
    Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. Available at http://www.grappanetwork.org. Accessed January 2011.

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Medicine and Therapeutics, Chinese University of Hong KongPrince of Wales HospitalShatinHong Kong

Personalised recommendations